Earli locates cancer early, when it is much more curable. Rather than rely on biomarkers that cancer may – or often may not – naturally provide, Earli's technology “forces” cancer cells to make a precise synthetic, non-human biomarker to localize the cancer. This new approach is called synthetic biopsy. In the future, the same platform might also be usable to trigger localized therapeutic responses inside the cancer.